DiscoverRx for BiotechRestoring Breath: Biologic Innovation for the Most Vulenerable Patients
Restoring Breath:  Biologic Innovation for the Most Vulenerable Patients

Restoring Breath: Biologic Innovation for the Most Vulenerable Patients

Update: 2025-10-28
Share

Description

Airway Therapeutics is taking on one of the toughest challenges in medicine - helping premature infants breathe on their own. In this episode of Rx for Biotech, CEO Marc Salzberg shares how zelpultide alfa, an investigational, first-in-class biologic, could transform care for newborns with bronchopulmonary dysplasia (BPD) and unlock a new future for respiratory medicine.
Comments 
In Channel
loading
00:00
00:00
x

0.5x

0.8x

1.0x

1.25x

1.5x

2.0x

3.0x

Sleep Timer

Off

End of Episode

5 Minutes

10 Minutes

15 Minutes

30 Minutes

45 Minutes

60 Minutes

120 Minutes

Restoring Breath:  Biologic Innovation for the Most Vulenerable Patients

Restoring Breath: Biologic Innovation for the Most Vulenerable Patients

Podcast Host Chris Leidli